Ascend Advanced Therapies is a gene-to-GMP CDMO specializing in development and manufacturing of advanced therapies, now owffering expanded commercial facilities and capabilities through the merger with ABL Inc., a portfolio company of EW Healthcare Partners
EW Healthcare Partners (EW) acquired Advanced BioScience Laboratories Inc. (ABL) as a cornerstone asset for creating a new, independent CDMO (contract development and manufacturing organization) platform in cell and gene therapy (CGT). ABL is a CDMO dedicated to advancing therapeutics, vaccines, and other biological products with significant experience working with diverse organizations including industry, government, and academic entities. ABL offers specialized manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines at its GMP facility in Rockville, MD.
In November 2024, EW partnered with Ascend to expand Ascend’s US capacity and capabilities through a merger with ABL along with a significant capital investment by EW to support continued growth of the combined entity.
The combination of Ascend and ABL creates a versatile CDMO platform supporting multiple CGT modalities as well as an expanded transatlantic footprint including three main sites in Rockville (MD), Alachua (FL) and Munich, Germany. The complementary services of the two organizations will further strengthen the service offering to customers and align more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated virus (AAV) production. The merger also expands fill/finish capacity in the US making the combined group one of the few suppliers with a comprehensive “R&D to commercial” offering in the market.
All content © 2025
Legal Disclaimer | Privacy Notice
Powered by 